This week, the ratings of 13 Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Agios Pharmaceuticals, Inc. (AGIO) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of AGIO stock.

Medivation, Inc. (MDVN) experiences a ratings drop this week, going from last week’s C to a D. Medivation, Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MDVN stock.

Slipping from a C to a D rating, AMAG Pharmaceuticals, Inc. (AMAG) takes a hit this week. AMAG Pharmaceuticals, Inc. utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company also gets F’s in earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMAG stock.

Epizyme, Inc. (EPZM) declines this week from a C to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

This week, Ironwood Pharmaceuticals, Inc. Class A’s (IRWD) rating worsens to a D from the company’s C rating a week ago. Ironwood Pharmaceuticals, Inc. Class A discovers, develops, manufactures, and commercializes marketed drugs. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of IRWD stock.

Regulus Therapeutics Inc. (RGLS) slips from a C to a D this week. Regulus Therapeutics Inc. focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

This is a rough week for Sangamo BioSciences, Inc. (SGMO). The company’s rating falls to D from the previous week’s C. Sangamo BioSciences, Inc. is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of SGMO stock.

GlycoMimetics, Inc. (GLYC) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of GLYC stock.

Mesoblast Limited Sponsored ADR’s (MESO) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MESO stock.

Aptose Biosciences Inc. (APTO) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of APTO stock.

This week, Aurinia Pharmaceuticals Inc. (AUPH) drops from a C to a D rating. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AUPH stock.

Slipping from a C to a D rating, Celsion Corporation (CLSN) takes a hit this week. Celsion Corporation is an innovative oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLSN stock.

Biota Pharmaceuticals, Inc. (BOTA) experiences a ratings drop this week, going from last week’s C to a D. Biota Pharmaceuticals, Inc. is an anti-infective drug development company with expertise in respiratory diseases, particularly influenza. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BOTA stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.